Gilead to acquire global rights of Trodelvy from Everest
Under the deal, Gilead has a chance to hire Everest staff working on the Trodelvy programme.
China
Latest in
China
TSB and CR Pharma partner for Covid-19 antibody therapy in China
The companies will expedite the stockpiling, channel distribution and offer access to hospitals for the antibody therapy.
Brii Bio introduces Covid-19 combination therapy in China
In a Phase III trial, the antibody combination offered a statistically significant 80% decline in hospitalisation and death.
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
invoX Pharma agrees to acquire biopharma firm F-star Therapeutics for $161m
Four programmes of F-star are currently in the clinic while various other undisclosed programmes are in the developmental stage.
China NMPA grants approval for BeiGene’s nasopharyngeal cancer therapy
The approval is based on clinical data from the Phase III RATIONALE 309 clinical trial of tislelizumab plus chemotherapy.
Everest’s Trodelvy receives approval for breast cancer in China
In a Phase IIb trial in 80 subjects, Trodelvy offered an overall response rate of 38.8%.
Sinovac Biotech receives WHO prequalification for polio vaccine
The vaccine is intended for active immunisation against polioviruses Type 1, 2, and 3 in infants.